69 results
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
formulations have been withdrawn from the U.S. market for reasons other than safety. There is extensive data on short term and chronic use of Proglycem
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, food pre-occupation
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
data on short term and chronic use of Proglycem in children with congenital hyperinsulinism, or CHI, and in adults with insulinoma. Insulinoma patients … symptom of PWS – hyperphagia – a chronic feeling of insatiable hunger. Other central effects of DCCR may improve various behavioral abnormalities
424B5
4hjfr fzfcjgdgjpg
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
e1o4ndfq39s20cj llgt
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
qa3966vn 331yjk5
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm
8-K
EX-99.1
9jors9
10 Jul 23
Regulation FD Disclosure
4:06pm
8-K
EX-99.1
syg8s n6hsl
9 May 23
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm
8-K
EX-99.1
05ft8 lx9
3 May 23
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
5:26pm
8-K
EX-99.1
gda1c us7q
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-99.1
9yi5e2d5
9 Nov 22
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:11pm
8-K
EX-99.1
openy172xf3ovy
3 Oct 22
Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of
9:00am
8-K
EX-99.1
7quavaw3gztci
10 Aug 22
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
bc70yu qlf
20 Jul 22
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
8:01am
8-K
EX-99.1
g8b3u8s pf1lwqsuzr1
10 May 22
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:01pm
8-K
EX-99.1
py3n3mzbtu28nupawx8
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
4aruzb1k4 9hgi5
30 Mar 22
Prospectus supplement for primary offering
5:21pm